JMP Securities analyst Jason Butler reiterated a Buy rating on Prothena (PRTA – Research Report) today and set a price target of $82.00. The company’s shares opened today at $56.58.
Butler covers the Healthcare sector, focusing on stocks such as Cytokinetics, Aquestive Therapeutics, and Athira Pharma. According to TipRanks, Butler has an average return of -9.8% and a 37.61% success rate on recommended stocks.
Prothena has an analyst consensus of Strong Buy, with a price target consensus of $81.13, which is a 43.39% upside from current levels. In a report released on November 9, Cantor Fitzgerald also maintained a Buy rating on the stock with a $91.00 price target.
See the top stocks recommended by analysts >>
PRTA market cap is currently $2.75B and has a P/E ratio of -17.02.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRTA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More on PRTA:
- Prothena downgraded to Sector Perform at RBC Capital on valuation
- Prothena downgraded to Sector Perform from Outperform at RBC Capital
- Prothena to Report Third Quarter 2022 Financial Results on November 3rd
- Prothena price target raised to $71 from $65 at Citi
- Prothena management to meet with Jefferies
